| Literature DB >> 8688697 |
Abstract
Levodopa remains the cornerstone for managing Parkinson's disease. Physician's preference usually determines the dopamine agonist chosen for the early phases of treatment. The concept of neuro-protection, however, remains unproven. A better understanding of the cause of the disease and treatment-related complications could make managing Parkinson's disease more rewarding.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8688697 PMCID： PMC2146376
Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275